Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Effect of cirrhosis and debrisoquin phenotype on the disposition and effects of pinacidil
Ist Teil von
Clinical pharmacology and therapeutics, 1986-12, Vol.40 (6), p.650-655
Ort / Verlag
New York, NY: Nature Publishing
Erscheinungsjahr
1986
Quelle
MEDLINE
Beschreibungen/Notizen
Pinacidil is an investigational vasodilator currently undergoing clinical trials as an antihypertensive agent. It is metabolized in humans to pinacidil N‐oxide. To determine whether pinacidil's metabolism or effects were influenced by either liver disease or the subject's debrisoquin phenotype, eight patients with chronic stable cirrhosis and 13 healthy subjects were studied. Seven of the healthy volunteers were extensive metabolizers of debrisoquin, whereas six were of the poor metabolizer phenotype. Neither the clearance of pinacidil nor the production of the N‐oxide was altered by the subjects' debrisoquin phenotype. Cirrhosis produced a 50% reduction in pinacidil's clearance (20.7 ± 1.4 vs. 42.1 ± 5.1 L/hr; P < 0.0005) and a prolongation in the elimination t½ from 3.9 ± 0.3 to 6.1 ± 0.6 hours (P < 0.01). Less pinacidil was metabolized to the N‐oxide metabolite in the patients with cirrhosis than in the normal individuals. Thus pinacidil's metabolism and clearance are reduced in patients with cirrhosis but are independent of debrisoquin phenotype.
Clinical Pharmacology and Therapeutics (1986) 40, 650–655; doi:10.1038/clpt.1986.240